This filing is a structural announcement with no immediate financial catalyst. Monitor for definitive licensing agreements with PsyLabs and any subsequent capital raises to fund TIRC's activities, given the company's limited cash runway and reliance on dilutive equity financing.
Price Chart
Executive Summary
Psyence Biomedical formed Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary to coordinate U.S. ibogaine development, including pharmaceutical-grade supply, regulatory engagement, and potential clinical trials. TIRC is positioned to hold U.S. rights to PsyLabs' ibogaine, subject to definitive licensing arrangements. This is a structural step to align with recent U.S. policy momentum for neuroplastogen research, but the company remains pre-revenue with no approved products and faces significant financing and regulatory risks, as highlighted in the prior annual report's bearish context of widening losses and dilutive equity reliance.
Key Facts
- Psyence Biomedical established Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary.
- TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs, subject to definitive licensing arrangements.
- CEO Jody Aufrichtig will also serve as CEO of TIRC; Dr. John Thorne appointed project lead.
- The formation follows U.S. policy developments including an April 2026 Executive Order and July 2026 federal implementation.
- The company remains pre-revenue with no FDA-approved products; ibogaine is a controlled substance without established safety/efficacy.
- Prior 20-F (June 2026) reported a net loss of $6.89M, cash of $7.49M, and reliance on a dilutive $100M equity line.
Financial Impact
No financial figures disclosed in this filing. Prior 20-F reported net loss of $6.89M and cash of $7.49M.
Risk Factors
- Definitive licensing arrangements with PsyLabs may not be completed on expected terms or timeline.
- Ibogaine remains a controlled substance; regulatory pathways are uncertain and subject to change.
- Company has no approved products, widening losses, and relies on dilutive equity financing (White Lion line) for operations.
- Nasdaq continued listing compliance risk remains a factor.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-099451 |
| Document: ea0305327-6k_psyence.htm | 0001213900-26-099451 |
| Document: 0001213900-26-099451-index-headers.html | 0001213900-26-099451 |
| Document: 0001213900-26-099451-index.html | 0001213900-26-099451 |
| Document: 0001213900-26-099451.txt | 0001213900-26-099451 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers